Modulation of cdk2, cyclin D1, p16INK4a, p21WAF and P27Kip1 expression in endothelial cells by TNF/IFNγ

Anticancer Research

Volumn 22, Issue 6 A, 2002, Pages 3159-3163

  Dormond, Olivier ^a   Lejeune, Ferdy J ^a   Ruegg, Curzio ^a,b  

^a University of Lausanne Medical Center   (Switzerland)

^b SWISS INST FOR EXP CANCER RESEARCH   (Switzerland)

Author keywords

Cdk2; Cyclin D1; Endothelial cells; P16INK4a; P21WAF; P27Kipl; TNF IFN

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 2; GAMMA INTERFERON; PROTEIN P16; PROTEIN P21; PROTEIN P27; TUMOR NECROSIS FACTOR;

ARTICLE; CELL ADHESION; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

BLOTTING, WESTERN; CDC2-CDC28 KINASES; CELL CYCLE; CELL CYCLE PROTEINS; CYCLIN D1; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; CYCLINS; DRUG SYNERGISM; ENDOTHELIUM, VASCULAR; FLOW CYTOMETRY; G1 PHASE; HUMANS; INTERFERON TYPE II; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; RECOMBINANT PROTEINS; RETINOBLASTOMA PROTEIN; TUMOR NECROSIS FACTOR-ALPHA; TUMOR SUPPRESSOR PROTEINS;

EID: 0036870091     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature 407: 249-57, 2000.
2. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ and Holash J: Vascular-specific growth factors and blood vessel formation. Nature 407: 242-8, 2000.
3. Eliceiri BP and Cheresh DA: Role of alpha v integrins during angiogenesis. Cancer J Sci Am 6 Suppl 3: S245-9, 2000.
4. Brooks PC, Clark RA and Cheresh DA: Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264: 569-71, 1994.
5. Max R, Gerritsen RR, Nooijen PT, Goodman SL, Sutter A, Keilholz U, Ruiter DJ and De Waal RM: Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas. Int J Cancer 71: 320-4, 1997.
6. Pasqualini R, Koivunen E and Ruoslahti E: Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol 15: 542-6, 1997.
7. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD and Li KC: Detection of tumor angiogenesis in vivo by alpha Vbeta3targeted magnetic resonance imaging. Nat Med 4: 623-6, 1998.
8. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH and Cheresh DA: Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96: 1815-22 1995.
9. Lienard D, Ewalenko P, Delmotte JJ, Renard N and Lejeune FJ High-dose recombinant tumor necrosis factor alpha in combinatior with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10: 52-60, 1992.
10. Lejeune F, Ruegg C and Lienard D: Clinical applications of TNFalpha in cancer. Curr Opin Immunol 10: 573-580, 1998.
11. Yilmaz A, Bieler G, Spertini O, Lejeune FJ and Ruegg C: Pulse treatment of human vascular endothelial cells with high doses ol tumor necrosis factor and interferon-gamma results in simultaneous synergistic and reversible effects on proliferation and morphology. Int J Cancer 77: 592-599, 1998.
12. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P and Lejeune FJ: Evidence for the involvement of endothelial cell integrin alpha-vbeta-3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med 4: 408-414, 1998.
13. Dormond O, Foletti A, Paroz C and Ruegg C: NSAIDs inhibit alpha Vbeta3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat Med 7: 1041-7, 2001.
14. Saegusa Y, Ziff M, Welkovich L and Cavender D: Effect of inflammatory cytokines on human endothelial cell proliferation. J Cell Physiol 142: 488-95, 1990.
15. Patterson C, Perrella MA, Endege WO, Yoshizumi M, Lee ME and Haber E: Downregulation of vascular endothelial growth factor receptors by tumor necrosis factor-alpha in cultured human vascular endothelial cells. J Clin Invest 98: 490-6, 1996.
16. Lopez -Marure R, Ventura JL, Sanchez L, Montano LF and Zentella A: Ceramide mimics tumour necrosis factor-alpha in the induction of cell cycle arrest in endothelial cells. Induction of the tumour suppressor p53 with decrease in retinoblastoma/protein levels. Eur J Biochem 267: 4325-33, 2000.
17. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323-30, 1995.
18. Hunter T and Pines J: Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell 79: 573-82, 1994.
19. Fahraeus R and Lane DP: The p16(INK4a) tumour suppressor protein inhibits alpha (v)beta(3) integrin-mediated cell spreading on vitronectin by blocking PKC-dependent localization of alpha(v)beta(3) to focal contacts. EMBO J 18: 2106-2118, 1999.
20. Okahashi N, Murase Y, Koseki T, Sato T, Yamato K and Nishihara T: Osteoclast differentiation is associated with transient upregulation of cyclin-dependent kinase inhibitors p21(WAF1/CIP1) and p27(KIP1). Journal of Cellular Biochemistry 80: 339-45, 2001.
21. Matsuoka M, Nishimoto I and Asano S: Interferon-gamma impairs physiologic downregulation of cyclin-dependent kinase inhibitor, p27Kip1, during Gl-phase progression in macrophages. Experimental Hematology 27: 203-9, 1999.
22. Gooch JL, Herrera RE and Yee D: The role of p21 in interferon gamma-mediated growth inhibition of human breast cancer cells. Cell Growth & Differentiation 11: 335-42, 2000.
23. Kominsky S, Johnson HM, Bryan G, Tanabe T, Hobeika AC, Subramaniam PS and Torres B: IFNgamma inhibition of cell growth in glioblastomas correlates with increased levels of the cyclindependent kinase inhibitor p21WAF1/CIP1. Oncogene 17: 2973-9, 1998.
24. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G and Cheresh DA: Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79: 1157-64, 1994.